Ikaros sets the threshold for negative B-cell selection by regulation of the signaling strength of the AKT pathway

Autor: Patrick A. H. Ehm, Stefan Horn, Konstantin Hoffer, Malte Kriegs, Michael Horn, Susanne Giehler, Marcus Nalaskowski, Christoph Rehbach, Martin A. Horstmann, Manfred Jücker

Publikováno v: Cell Communication and Signaling, Vol 22, Iss 1, Pp 1-23 (2024)

Abstract Inhibitory phosphatases, such as the inositol-5-phosphatase SHIP1 could potentially contribute to B-cell acute lymphoblastic leukemia (B-ALL) by raising the threshold for activation of the autoimmunity checkpoint, allowing malignant cells wi

Externí odkaz: https://doaj.org/article/0e544bc1fd344d7d8ce0baab81ce998e

The Prognostic Effect of IKZF1 Deletions in ETV6::RUNX1 and High Hyperdiploid Childhood Acute Lymphoblastic Leukemia

Autor: Anna Østergaard, Amir Enshaei, Rob Pieters, Ajay Vora, Martin A. Horstmann, Gabriele Escherich, Bertil Johansson, Mats Heyman, Kjeld Schmiegelow, Peter M. Hoogerbrugge, Monique L. den Boer, Roland P. Kuiper, Anthony V. Moorman, Judith M. Boer, Frank N. van Leeuwen

Publikováno v: HemaSphere, Vol 7, Iss 5, p e875 (2023)

IKZF1 deletions are an established prognostic factor in childhood acute lymphoblastic leukemia (ALL). However, their relevance in patients with good risk genetics, namely ETV6::RUNX1 and high hyperdiploid (HeH), ALL remains unclear. We assessed the p

Externí odkaz: https://doaj.org/article/5645c5c18f97430d84ab7aaaba94a6bf

Results of CoALL 07-03 study childhood ALL based on combined risk assessment by in vivo and in vitro pharmacosensitivity

Autor: Franziska Schramm, Udo zur Stadt, Martin Zimmermann, Norbert Jorch, Arnulf Pekrun, Arndt Borkhardt, Thomas Imschweiler, Holger Christiansen, Jörg Faber, Irene Schmid, Tobias Feuchtinger, Gerhard Beron, Monique L. den Boer, Rob Pieters, Martin A. Horstmann, Gritta E. Janka-Schaub, Gabriele Escherich

Publikováno v: Blood Advances, Vol 3, Iss 22, Pp 3688-3699 (2019)

Abstract: We conducted a clinical trial and report the long-term outcome of 773 children with acute lymphoblastic leukemia upon risk-adapted therapy accrued in trial CoALL 07-03 (from the Cooperative Study Group for Childhood Acute Lymphoblastic Leuk

Externí odkaz: https://doaj.org/article/d42a2096dac14256845efb293f66f89b

Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients

Autor: Blanca Scheijen, Judith M. Boer, René Marke, Esther Tijchon, Dorette van Ingen Schenau, Esmé Waanders, Liesbeth van Emst, Laurens T. van der Meer, Rob Pieters, Gabriele Escherich, Martin A. Horstmann, Edwin Sonneveld, Nicola Venn, Rosemary Sutton, Luciano Dalla-Pozza, Roland P. Kuiper, Peter M. Hoogerbrugge, Monique L. den Boer, Frank N. van Leeuwen

Publikováno v: Haematologica, Vol 102, Iss 3 (2017)

Deletions and mutations affecting lymphoid transcription factor IKZF1 (IKAROS) are associated with an increased relapse risk and poor outcome in B-cell precursor acute lymphoblastic leukemia. However, additional genetic events may either enhance or n

Externí odkaz: https://doaj.org/article/4b9e33dbdf0346af888f8b42df273b6a

A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia

Autor: Rob Pieters, Christine J. Harrison, Hanne Vibeke Marquart, John Moppett, Ajay Vora, Martin A. Horstmann, Gabriele Escherich, Jack Bartram, Jeremy Hancock, Mats Heyman, Monique L. den Boer, Amir Enshaei, David O'Connor, Judith M. Boer, Claire Schwab, Ulrika Norén-Nyström, Hester A. de Groot-Kruseman, Rachael Hough, Kjeld Schmiegelow, Sujith Samarasinghe, Anthony V. Moorman

Publikováno v: Enshaei, A, O'Connor, D, Bartram, J, Hancock, J, Harrison, C J, Hough, R, Samarasinghe, S, den Boer, M L, Boer, J M, de Groot-Kruseman, H A, Marquart, H V, Noren-Nystrom, U, Schmiegelow, K, Schwab, C, Horstmann, M A, Escherich, G, Heyman, M, Pieters, R, Vora, A, Moppett, J & Moorman, A V 2020, ' A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia ', Blood, vol. 135, no. 17, pp. 1438-1446 . https://doi.org/10.1182/blood.2019003191

Risk stratification is essential for the delivery of optimal treatment in childhood acute lymphoblastic leukemia. However, current risk stratification algorithms dichotomize variables and apply risk factors independently, which may incorrectly assume

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3948e412ff74a89955892539af09aab
https://doi.org/10.1182/blood.2019003191